Replies to post #245696 on Biotech Values

[dewophile]

How could a pre approval study possibly tease out such a rare risk it’s impractical
I’m glad a majority realized you can only really do this in the post marketing setting when you have a million plus patients dosed

[DewDiligence]

PFE’s RSV-vaccine studies published in NEJM:

https://www.nejm.org/doi/full/10.1056/NEJMoa2213836 (adult vaccine)

https://www.nejm.org/doi/full/10.1056/NEJMoa2216480 (maternal vaccine)